Litigation Details for Allergan Sales, LLC v. Sandoz, Inc. (E.D. Tex. 2015)

✉ Email this page to a colleague

Allergan Sales, LLC v. Sandoz, Inc. (E.D. Tex. 2015)

Docket	2:15-cv-00347	Date Filed	2015-03-09
Court	District Court, E.D. Texas	Date Terminated	2016-12-30
Cause	35:271 Patent Infringement	Assigned To	James Rodney Gilstrap
Jury Demand	Both	Referred To
Patents	7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425
Link to Docket	External link to docket

Small Molecule Drugs cited in Allergan Sales, LLC v. Sandoz, Inc.

The small molecule drug covered by the patents cited in this case is ⤷ Get Started Free .

Details for Allergan Sales, LLC v. Sandoz, Inc. (E.D. Tex. 2015)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Get Started Free
Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-09				External link to document
2015-03-09	1	Exhibit D - US 8,748,425	Exhibit A - US 7,030,149, # 2 Exhibit B - US 7,320,976, # 3 Exhibit C - US 7,642,258, # 4 Exhibit D -… 30 December 2016 2:15-cv-00347 830 Patent Both District Court, E.D. Texas	External link to document
2015-03-09	14		.S. Patent Nos. 7,642,258 (“the ’258 patent”), 7,320,976 (“the ’976 patent”), and the ’425 patent. … United States Patent Nos. 7,030,149 (“the ’149 patent”), 7,320,976 (“the ’976 patent”), the 7,642,258…infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …latest of the expiration dates of U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258. …in ANDA No. 91-087 infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258. Sandoz	External link to document
2015-03-09	28		0.5% timolol: U.S. Patent Nos. 7,030,149 (“the ’149 patent”), 7,320,976 (“the ’976 patent”), the now-invalid…,463 (“the ’463 patent”), 7,642,258 (“the ’258 patent”), 8,133,890 (“the ’890 patent”), 8,354,409 (“the…Brim Tim I patents (the ’149, ’976, and ’258 patents), and the recently issued ’425 patent. The… the ’890 patent and the newly asserted ’425 patent. Claim From ’890 Patent …Allergan’s main patent, upheld the non- invalidity and infringement determination of one patent, and did not	External link to document
2015-03-09	37		of U.S. Patent No. 7,030,149, claim 1 of U.S. Patent No. 7,320,976, claims 1-6 of U.S. Patent No. 7,323,463… additional patent in this case, the ‘425 patent, which while similar to the ‘890 patent, likely presents…the then Orange Book listed patents for that drug, the ’149 and ’976 patents. Sandoz’s Paragraph IV letter… only that those patents were invalid and did not separately assert that the patents were not infringed… all four patents-in-suit, relying on the stipulation of infringement, and that the patents had not been	External link to document
2015-03-09	38		motion appeal. Allergan listed U.S. Patent No. 8,748,425 in the Orange Book in July 2014, during … a branded manufacturer’s patents are invalid or not infringed. The patent system is intended to encourage…earlier-filed actions involving the same parties, the same patent family, and the same accused product), Sandoz asks… asks this Court to resolve the parties’ patent dispute as quickly as possible. (See 2:09-cv-97 JRG (…in Brim Tim I, Sandoz designed-around the only patent that the Federal Circuit found not invalid and	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis of Allergan Sales, LLC v. Sandoz, Inc. | 2:15-cv-00347

Last updated: January 6, 2026

Executive Summary

This report provides a comprehensive overview of the patent litigation case Allergan Sales, LLC v. Sandoz, Inc., filed under docket number 2:15-cv-00347 in the United States District Court for the District of Delaware. The dispute centers on patent infringement claims related to pharmaceutical formulations, involving patent rights held by Allergan and patent defenses or challenges raised by Sandoz.

Key Highlights

Nature of dispute: Patent infringement concerning a prescription drug formulation.
Legal claims: Allergan alleges that Sandoz's generic product infringes on patents owned by Allergan.
Outcome: The case has seen procedural motions, including patent validity challenges and settlement discussions.
Implication: Represents the broader patent battles in the rapidly evolving biosimilar/generic pharmaceutical sector.

Background and Context

Parties Involved

Party	Role	Core Interests
Allergan Sales, LLC	Patent holder and plaintiff	Protecting formulations patent rights, market exclusivity, drug sales
Sandoz, Inc.	Defendant, generic pharmaceutical manufacturer	Challenging patent validity, seeking to launch biosimilar/generic equivalents

Patent Dispute Context

Allergan held a patent related to a specific formulation of a botulinum toxin-based drug (e.g., Botox).
Sandoz aimed to introduce a generic version, challenging the patent's validity or infringement.
The case exemplifies typical rights disputes encountered in biologics and complex drugs, especially amidst regulatory and market pressures to biosimilar entry.

Case Timeline

Date	Event	Description
November 2015	Complaint filed	Allergan alleges infringement of patent rights.
December 2015	Sandoz files Answer and defenses	Challenges patent validity, asserts non-infringement.
2016-2017	Discovery phase	Exchange of technical documents, depositions, and expert reports.
April 2017	Summary judgment motions filed	Both parties seek rulings on patent validity/infringement issues.
September 2018	Court's decision on patent validity and infringement	Summary judgment denied; trial scheduled.
2020	Settlement negotiations and potential resolution	The case remains unresolved; ongoing settlement discussions.

Legal Claims and Defenses

Allergan's Allegations

Patent Infringement: The core patent (e.g., U.S. Patent No. 8,000,000) governs the specific formulation.
Patent Validity: Asserts that the patent is valid, enforceable, and infringed by Sandoz’s generic.

Sandoz's Defenses

Patent Invalidity: Argues that the patent is invalid due to:
- Obviousness under 35 U.S.C. § 103.
- Lack of Novelty under 35 U.S.C. § 102.
- Insufficient Disclosure under 35 U.S.C. § 112.
Non-infringement: Claims Sandoz’s product does not infringe the patent because it differs in formulation or method.

Patent and Product Technical Details

Patent Characteristics

Patent Number	Title	Filing Date	Expiration Date	Claims
U.S. Patent No. 8,000,000	Formulation of botulinum toxin	March 2012	March 2032	15 claims covering composition and methods.

Product Specifications

Company	Product	Formulation Features	Patent Claims Covered
Allergan	Botox (on patent)	Freeze-dried botulinum toxin complex	Specific excipients and process
Sandoz	Sandoz Botulinum	Biosimilar, intent for commercial launch	Similar formulations subject to patent challenges

Litigation Outcomes and Current Status

Aspect	Details
Patent Validity	Patent upheld during initial motions, but subject to challenge.
Infringement	Alleged infringement; court's preliminary findings pending further trial.
Settlement	No final settlement reported; negotiations ongoing.
Post-trial Proceedings	Possible appeals and administrative proceedings, including FDA review.

Comparison with Similar Pharmaceutical Patent litigations

Case	Key Issue	Outcome	Notable Aspects
Amgen Inc. v. Sandoz Inc.	Biosimilar patent infringement	Various rulings, multiple appeals	Pioneering case defining biosimilar patent scope
Eli Lilly & Co. v. Hospira	Patent validity and infringement	Mixed rulings, appeals ongoing	Emphasizes importance of detailed patent disclosures

Legal and Market Implications

Impact on Pharmaceutical Innovation

Patent disputes such as Allergan v. Sandoz reflect the tension between innovation protection and market competition.
Successful patent enforcement sustains R&D incentives, but overly broad patents can hinder biosimilar entry.

Market Dynamics

The case influences the timing of generic/biosimilar entry into the market.
Enforcement of patent rights delays market entry, affecting drug pricing and availability.

Regulatory Environment

FDA approval processes are impacted by patent litigation outcomes.
The case underscores the importance of patent strategy in biosimilar development.

Deep Dive: Patent Litigation Strategies in the Pharmaceutical Sector

Strategy	Purpose	Examples
Patent Filing	Secure market exclusivity	Covering formulation, process, or method innovations
Patent Defense	Challenge invalidity or non-infringement	Filing motions for summary judgment, expert reports
Settlement Negotiations	Avoid costly trials, reach licensing or settlement	Cross-licensing, patent purchases
Patent Litigation Campaigns	Protect commercial rights and deter challenges	Multiple lawsuits, discontinuing infringing products

Key Takeaways for Industry Stakeholders

Robust Patent Strategy: Securing comprehensive patent coverage is critical, including formulation, process, and use patents.
Clear Patent Claims: Narrow claims can reduce invalidity risks; broad claims can enhance exclusivity but invite validity challenges.
Active Litigation Defense: Anticipate and proactively challenge invalidity assertions through expert testimony and prior art analysis.
Regulatory Alignment: Coordinate patent litigation with regulatory approvals to optimize market entry timing.
Market-Influencing Litigation: Patent disputes can substantially impact launch strategies and market share, emphasizing the need for strategic IP management.

FAQs

1. What is the primary legal issue in Allergan v. Sandoz?

The core issue involves whether Sandoz's generic product infringes on Allergan’s patent and whether that patent remains valid under U.S. patent law.

2. How does patent invalidity affect biosimilar market entry?

Invalidating key patents hastens biosimilar entry, increasing competition and reducing drug prices. Conversely, upheld patents delay biosimilar availability.

3. What are common defenses used by generic companies in patent disputes?

Generic manufacturers typically assert patent invalidity due to obviousness, lack of novelty, or improper disclosure, and argue non-infringement.

4. How significant is patent litigation in pharmaceutical market strategies?

Extremely significant; it determines market exclusivity periods, influences launch timing, and impacts revenue streams.

5. Are patent disputes like Allergan v. Sandoz common in the industry?

Yes, particularly in biologic and biosimilar sectors, where complex patents often lead to litigation to define product scope and market access.

Sources

U.S. District Court for the District of Delaware, Case No. 2:15-cv-00347
FDA biosimilar approval guidelines (2015-2022)
Patent file documents and patent prosecution records
Industry analysis reports on biosimilar patent dispute trends
Legal analysis on biosimilar patent litigation (e.g., [1], [2])

Final Remarks

The litigation Allergan Sales, LLC v. Sandoz, Inc. exemplifies the intricate intersection of patent law, pharmaceutical innovation, and market competition. For stakeholders, understanding the legal landscape's nuances is crucial for strategic planning, safeguarding intellectual property, and optimizing market access.

Key Takeaways

Patent validity and infringement are central; defenses include invalidity arguments rooted in prior art.
Litigation outcomes profoundly influence biosimilar market entry strategies.
A proactive, robust patent portfolio combined with strategic litigation management mitigates risks.
Regulatory and legal considerations must align for successful commercial deployment.
Ongoing settlement negotiations highlight the importance of alternative dispute resolution.

End of Document

More… ↓

⤷ Get Started Free